Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Merck Dissolves Two Pharmaceutical Pacts

by Lisa M. Jarvis
March 22, 2010 | A version of this story appeared in Volume 88, Issue 12

As part of a pipeline revamp, Merck & Co. is returning assets to partners. Memphis-based GTx has reacquired the rights to a selective androgen receptor modulator program, including Ostarine, which has completed Phase II clinical trials to treat loss of body mass in cancer patients. GTx is now planning a Phase III trial of the drug. Separately, Merck paid Dynavax $4 million to cover expenses related to winding down their collaboration on the hepatitis B vaccine Heplisav. Merck ended the partnership after FDA put a trial on hold last year. The agency later allowed Dynavax to proceed, and the company now says it expects to file for approval in the third quarter of 2011.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.